Drug Profile
Epratuzumab-cys-tesirine - ADC therapeutics
Alternative Names: ADCT-602; Epratuzumab-cys-SG3249; hLL2-cys-PBD; hLL2-cys-SG3249Latest Information Update: 10 Jan 2023
Price :
$50
*
At a glance
- Originator ADC Therapeutics
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma
- Preclinical B-cell lymphoma
Most Recent Events
- 10 Dec 2022 Efficacy and adverse events data from a phase I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 11 Dec 2021 Safety, efficacy and pharmacokinetics data from a phase I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in Switzerland (IV)